Targeting PqsD is a promising novel approach to disrupt bacterial cell-to-cell-communication in Pseudomonas aeruginosa. In search of selective PqsD inhibitors, two series of benzamidobenzoic acids  one published as RNAP inhibitors and the other as PqsD inhibitors  were investigated for inhibitory activity toward the respective other enzyme. Additionally, novel derivatives were synthesized and biologically evaluated. By this means, the structural features needed for benzamidobenzoic acids to be potent and, most notably, selective PqsD inhibitors were identified. The most interesting compound of this study was the 3-Cl substituted compound 5 which strongly inhibits PqsD (IC 50 6.2 µM) while exhibiting no inhibition of RNAP.
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Introduction
Increasing resistance of bacteria against clinically used antibiotics provoke an urgent need for new antibacterial drugs and innovative therapeutic options [1, 2] . An established method is the induction of bacterial growth retardation or cell death by inhibiting pivotal enzymes [3] . A disadvantage of this therapy is selective pressure causing rapid emergence of resistance [3, 4] .
This should be different in a more recent approach to combat bacterial infections [5] . By intervening with the bacterial cell-to-cell-communication system the production of virulence factors and the biofilm formation can be reduced [5] . A newly described strategy to interfere with the Pseudomonas Quinolone Signal (PQS) communication system in Pseudomonas aeruginosa, is the inhibition of PqsD, which is responsible for the biosynthesis of the important signal molecule 2-heptyl-4-quinolone (HHQ) [6] .
Recently, we described a series of potent novel RNA polymerase (RNAP) inhibitors [7] derived from a known inhibitor of PqsD [6] . These compounds containing a benzamidobenzoic acid core were shown to inhibit RNAP in vitro in the low micromolar range (IC 50 around 10 µM) [7] . Due to their origin and their structural similarity to the PqsD inhibitors recently published by Weidel et al. [8] , we expected this new class of RNAP inhibitors also to inhibit PqsD and tested the compounds in our PqsD in vitro assay for inhibitory activity. Indeed, we found most of them to be very potent.
Biological results
The inhibitory activities of compounds 1─50 against RNAP and PqsD are displayed in Table   1 and 2.
The unsubstituted anthranilic acid 1 has already been described as a potent inhibitor of PqsD [6] and RNAP [7] . Removal of the 3'-OPh or 4'-Ph part of the compound led to 2 and 3, which only moderately inhibited the two enzymes. Removal of both moieties resulted in the completely inactive compound 4. In the following, different substituents were introduced into Motivated by these initial interesting results several new analogues with further modifications were synthesized and evaluated. In a first step the carboxylic acid group of compound 22, which is a very potent inhibitor of both enzymes, was exchanged by CONH 2 (36), CN (37) or COOMe (38). As these modifications led to severe solubility problems, no further COOHreplacements were performed. Shifting the carboxylic acid group of 2 to meta position (39) resulted in a slight increase of activity for RNAP inhibition. However, introduction of a bromo substituent in 4-or 5-position of 39 leading to compounds 40 and 41 reduced inhibitory activity for both enzymes compared to the brominated compounds with the carboxylic acid group in ortho position (11, 12 and 22─24). A shift of the carboxylic acid group of 2 to the para position (42) resulted in a hardly soluble compound with a weak RNAP inhibition.
In the next step a bioisosteric replacement of the anthranilic acid phenyl ring by differently substituted thiophenes was performed. The unsubstituted thiophene compounds 43─45 showed a considerably improved PqsD inhibitory potency, especially 43, whereas only for 45 a slightly improved RNAP inhibition was found. Interestingly, adding substituted and unsubstituted phenyl rings to the free positions of the thiophene (46─49) strongly enhanced RNAP inhibition while PqsD inhibitory activity was concurrently diminished.
Finally, we replaced the phenyl rings connecting amide function of highly potent 22 by a sulfonamide linker. The resulting compound 50 exhibited a reasonable increase of PqsD inhibition while the RNAP inhibitory potency was retained.
To make the SAR complete, the potent PqsD inhibitors published by Weidel et al. [8] (51─86, SI) were tested for RNAP inhibition. Interestingly, most of the compounds were found not to inhibit RNAP at a concentration of 200 µM or at their highest soluble concentration (SI).
Only some compounds containing a 5-NO 2 substituent (64), a substituted phenyl ring in 5-position (74─77), a 3'-SO 2 NEtBenzyl (86) or a 4'-SO 2 NEt 2 moiety (65) show a weak to moderate inhibition of RNAP (SI).
Discussion
In this paper we could demonstrate that it is possible to convert the unsubstituted benzamidobenzoic acid 4 into potent PqsD inhibitors by structural modifications. As already shown for RNAP [7] substituents in 3'-or 4'-position are also a minimum requirement for a moderate inhibition of PqsD (2, 3) . The combination of substituents in both positions, however, results in very potent PqsD inhibitor 1 [6] . Another very effective way to increase potency of 2 and 3 is the introduction of lipophilic electron withdrawing substituents or phenyl rings in 4-or 5-position of the anthranilic acid core (6─15, 19─27). The same phenomenon has already been described for the sulfamoylbenzamidobenzoic acids [8] .
However, the disadvantage all described modifications have in common is that they do not selectively enhance the inhibitory potency for PqsD, but also for RNAP. This is an unwanted effect of the inhibitors, as antibacterial activity caused by potent RNAP inhibition would provoke selective pressure [3] , which is in contradiction with the anti-virulence concept by PqsD inhibition. Therefore it is of particular interest that the presented series of compounds also contain structural modifications which selectively enhance PqsD inhibitory potency and do not affect or even decrease RNAP inhibition.
For example the introduction of a 3-Cl substituent (5), which strongly increases PqsD inhibition, leads to a total loss of activity for RNAP. A similar observation is made for the introduction of a 5-OH group (31), which also results in a very potent and highly PqsD selective compound. The introduction of a OH group in 6-position (35) causes a slight increase in RNAP inhibition, however, improvement of PqsD inhibitory activity is much stronger leading to a compound which is about 50 times more potent on PqsD than on RNAP.
Apart from introduction of substituents into the anthranilic acid core, selectivity can be gained by bioisosteric replacement. Via exchange of the anthranilic acid phenyl ring by a thiophene, potent and selective PqsD inhibitors can be obtained without affecting the moderate RNAP inhibitory activity (esp. 43). However, the introduction of a phenyl substituent into 43 should be avoided, as this modification results in a loss or even an inversion of selectivity. A further option to gain selectivity is the replacement of the amide function by a sulfonamide. This slightly increases PqsD inhibition without affecting RNAP activity.
Regarding the recently published PqsD inhibitors [8] (51─86, SI) it is striking that most of these compounds do not contain any of the structural features that we identified in this study to be causing PqsD selectivity. Instead, many of them contain substituents that are also beneficial for RNAP inhibition in the class of benzamidobenzoic acids, as described earlier [7] (e.g. Br, Cl, CF 3 ). This raised the question whether these sulfamoylbenzamidobenzoic acids are, beside their strong inhibition of PqsD, also selective. Interestingly, only few of them slightly or moderately inhibit RNAP. This reveals that in the class of benzamidobenzoic acids selectivity between PqsD and RNAP can also be gained by variation of R carrying a 4'-SO 2 N(n-Pr) 2 substituent is a quite potent RNAP inhibitor [7] . This results in the conclusion that a 4'-sulfonamide substituent in not suitable for selective PqsD inhibition.
Conclusion
As emergence of bacterial resistance against clinically used antibiotics is becoming a major public health problem [1] , the novel anti-virulence concept by PqsD inhibition is of special interest [10] . For following this strategy and avoiding selective pressure it is important that PqsD inhibitors do not cause bacterial cell death by inhibition of pivotal enzymes [3] like RNAP. In this work we presented a series of new potent PqsD inhibitors of the benzamidobenzoic acid class and identified the structural modifications that are necessary to convert potent RNAP inhibitors into selective PqsD inhibitors. It is striking that already simple bioisosteric replacements led to a notable gain of selectivity. For further optimization of potency and selectivity it is conceivable to combine some of these modifications into one structure. As the in vitro PqsD inhibitory activities of our compounds are promising, they will be further evaluated in vivo.
Experimental Section

General Directions
Chemical names follow IUPAC nomenclature. Starting materials were purchased from SigmaAldrich, Acros, Maybridge, Combi Blocks, Fluka, ABCR, Alfa Aesar, Apollo and were used without purification.
Column chromatography (CC) was performed on silica gel (70─200 μm), preparative thin layer chromatography (TLC) on 1 mm SIL G-100 UV254 glass plates (Macherey-Nagel), and reaction progress was monitored by TLC on Alugram SIL G UV254 (Macherey-Nagel). The reported yields are the isolated yields of purified material and are not optimized.
Purity of compounds 35 to 50 was determined using LC/MS as follows:
The SpectraSystems®-LC-system consisted of a pump, an autosampler, and a UV detector.
Mass spectrometry was performed on a MSQ® electro spray mass spectrometer (Thermo Fisher, Dreieich, Germany). The system was operated by the standard software Xcalibur®. A RP C18 NUCLEODUR® 100-5 (125 x 3 mm) column (Macherey-Nagel GmbH, Duehren, Germany) was used as stationary phase. All solvents were HPLC grade.
Solvent system: In a gradient run the percentage of acetonitrile (containing 0.1% triflouroacetic acid) in 0.1% triflouro-acetic acid was increased from an initial concentration of 0% at 0 min to 100% at 15 min and kept at 100% for 5 min.
The injection volume was 10 µL and flow rate was set to 800 µL/min. MS analysis was carried out at a spray voltage of 3800 V, a capillary temperature of 350 °C and a source CID of 10 V. Spectra were acquired in positive mode from 100 to 1000 m/z and at 254 nm for the UV trace.
All tested compounds have >95% chemical purity as measured by HPLC.
Melting points were determined on a Stuart Scientific melting point apparatus SMP3 and are uncorrected.
Chemistry
General Procedure for the synthesis of methyl aminobenzoates 39b−42b. A solution
of the appropriate 2-aminobenzoic acid (1 equiv) in MeOH was cooled to 0 °C followed by a dropwise addition of thionyl chloride (2.5 equiv). The mixture was refluxed for 24 h. After evaporation of the solvent and neutralization by addition of a saturated aqueous NaHCO 3 solution, the mixture was extracted with EtOAc and the combined organic layers were dried over MgSO 4 . Purification by CC (n-hexane/EtOAc) provided the title compounds. 
General Procedures for the synthesis of methyl benzamidobenzoate or methyl benzamidothiophenecarboxylate derivatives 36−38, 39a−49a (amide coupling reactions).
Three different amide coupling procedures were used to obtain the title compounds: 
General
Procedure for the synthesis of 37, 40a, 44a47a, 49a. The appropriate alkyl aminobenzoate or alkyl aminothiophenecarboxylate (1 equiv) and a catalytic amount of DMAP were added to a suspension of the acyl chloride (1.5 equiv) in pyridine under a N 2 atmosphere. The reaction mixture was stirred for 18 h at room temperature and 2 M HCl was added. The mixture was extracted with EtOAc, the combined organic layers washed with saturated NaHCO 3 and dried over MgSO 4 . For purification the solvent was evaporated and the remaining solid was suspended in MeOH. After filtration the precipitate was washed with MeOH (and EtOAc in case of 45a) to provide the pure compound After filtration the precipitate was washed with MeOH to yield the pure compound. t R = 11.17 min; 99.0% pure (UV). [12] beige solid, yield: 92%. Mp: 337 °C (decomposition). [13] yellow solid, yield: 87%. Mp: 242243 °C. 
N-(4-Bromo-2-cyanophenyl)-[1,1'-biphenyl]-4-carboxamide
Methyl 3-([1,1'-biphenyl]-4-ylcarboxamido)-5-(4-chlorophenyl)thiophene-2-carboxylate
N-(4-Bromo-2-carbamoylphenyl)-[1,1'-biphenyl]-4-carboxamide
General
3-([1,1'-Biphenyl]-4-ylcarboxamido)-4-bromobenzoic acid
4-([1,1'-Biphenyl]-4-ylcarboxamido)benzoic acid (42)
3-([1,1'-Biphenyl]-4-ylcarboxamido)thiophene-2-carboxylic acid (43)
Biology
RNAP transcription inhibition assay. RNAP transcription inhibition assay was performed as described previously [9, 11] .
PqsD inhibition assay. PqsD inhibition assay was performed as described previously [8] .
Figure Captions
Figure 1. A recently described series of potent novel RNA polymerase (RNAP) inhibitors (II) [7] was derived from a known PqsD inhibitor (I) [6] . The compounds consisting of a benzamidobenzoic acid core are structurally very similar to the class of PqsD inhibitors (III) published by Weidel et al. [8] . This raised the question about selectivity: Do the compounds from class II also inhibit PqsD and are the molecules from class III inhibitors of RNAP? Figure 2 . Structural modifications generating selectivity in favor of PqsD inhibition over RNAP inhibition in the class of benzamidobenzoic acids
